{"id":32124,"date":"2025-04-21T15:02:58","date_gmt":"2025-04-21T07:02:58","guid":{"rendered":"https:\/\/flcube.com\/?p=32124"},"modified":"2025-04-21T15:02:59","modified_gmt":"2025-04-21T07:02:59","slug":"asieris-pharmaceuticals-reports-strong-2024-financial-results-for-urogenital-cancer-drugs","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=32124","title":{"rendered":"Asieris Pharmaceuticals Reports Strong 2024 Financial Results for Urogenital Cancer Drugs"},"content":{"rendered":"\n<p>hina-based urogenital cancer specialist Asieris Pharmaceuticals (<a href=\"https:\/\/www.google.com\/finance\/quote\/688176:SHA\">SHA: 688176<\/a>) has released its 2024 financial report. In its first year of commercialization, the company achieved revenues of RMB 202 million (USD 27.7 million) and maintained a cash reserve of RMB 1.89 billion (USD 260 million). Its flagship products, Ouyoubi (a neratinib biosimilar) and Dipaite (a pazopanib biosimilar), demonstrated impressive market uptake, covering 1,000 and 500 target hospitals respectively. Ouyoubi secured a 27% market share, while Dipaite achieved a 12% share of their respective originators.<\/p>\n\n\n\n<p><strong>Product Pipeline and Innovation<\/strong><br>Asieris Pharma\u2019s pipeline currently comprises 12 products and 16 investigational programs. APL-1702, a drug-device combination for photodynamic non-surgical treatment of cervical high-grade squamous intraepithelial lesions (HSIL), is under regulatory review in China. Hexvix (APL-1706), a diagnostic imaging agent for photodynamic blue light cystoscopy in bladder cancer detection, received NMPA approval in November 2024. Market launches for these innovative products are imminent.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/H2_AN202504181658539245_1.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of H2_AN202504181658539245_1.\"><\/object><a id=\"wp-block-file--media-8e5158d9-04ee-4372-94a4-6b3c6b8cfa85\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/H2_AN202504181658539245_1.pdf\">H2_AN202504181658539245_1<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/H2_AN202504181658539245_1.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-8e5158d9-04ee-4372-94a4-6b3c6b8cfa85\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>hina-based urogenital cancer specialist Asieris Pharmaceuticals (SHA: 688176) has released its 2024 financial report. In&#8230;<\/p>\n","protected":false},"author":1,"featured_media":32126,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[316,27,1127],"class_list":["post-32124","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-asieris-pharmaceuticals","tag-finanical-reports","tag-sha-688176"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Asieris Pharmaceuticals Reports Strong 2024 Financial Results for Urogenital Cancer Drugs - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"hina-based urogenital cancer specialist Asieris Pharmaceuticals (SHA: 688176) has released its 2024 financial report. In its first year of commercialization, the company achieved revenues of RMB 202 million (USD 27.7 million) and maintained a cash reserve of RMB 1.89 billion (USD 260 million). Its flagship products, Ouyoubi (a neratinib biosimilar) and Dipaite (a pazopanib biosimilar), demonstrated impressive market uptake, covering 1,000 and 500 target hospitals respectively. Ouyoubi secured a 27% market share, while Dipaite achieved a 12% share of their respective originators.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=32124\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Asieris Pharmaceuticals Reports Strong 2024 Financial Results for Urogenital Cancer Drugs\" \/>\n<meta property=\"og:description\" content=\"hina-based urogenital cancer specialist Asieris Pharmaceuticals (SHA: 688176) has released its 2024 financial report. In its first year of commercialization, the company achieved revenues of RMB 202 million (USD 27.7 million) and maintained a cash reserve of RMB 1.89 billion (USD 260 million). Its flagship products, Ouyoubi (a neratinib biosimilar) and Dipaite (a pazopanib biosimilar), demonstrated impressive market uptake, covering 1,000 and 500 target hospitals respectively. Ouyoubi secured a 27% market share, while Dipaite achieved a 12% share of their respective originators.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=32124\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-21T07:02:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-21T07:02:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2109.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32124#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32124\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Asieris Pharmaceuticals Reports Strong 2024 Financial Results for Urogenital Cancer Drugs\",\"datePublished\":\"2025-04-21T07:02:58+00:00\",\"dateModified\":\"2025-04-21T07:02:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32124\"},\"wordCount\":152,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32124#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2109.webp\",\"keywords\":[\"Asieris Pharmaceuticals\",\"Finanical Reports\",\"SHA: 688176\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32124#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32124\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=32124\",\"name\":\"Asieris Pharmaceuticals Reports Strong 2024 Financial Results for Urogenital Cancer Drugs - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32124#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32124#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2109.webp\",\"datePublished\":\"2025-04-21T07:02:58+00:00\",\"dateModified\":\"2025-04-21T07:02:59+00:00\",\"description\":\"hina-based urogenital cancer specialist Asieris Pharmaceuticals (SHA: 688176) has released its 2024 financial report. In its first year of commercialization, the company achieved revenues of RMB 202 million (USD 27.7 million) and maintained a cash reserve of RMB 1.89 billion (USD 260 million). Its flagship products, Ouyoubi (a neratinib biosimilar) and Dipaite (a pazopanib biosimilar), demonstrated impressive market uptake, covering 1,000 and 500 target hospitals respectively. Ouyoubi secured a 27% market share, while Dipaite achieved a 12% share of their respective originators.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32124#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32124\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32124#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2109.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2109.webp\",\"width\":1080,\"height\":608,\"caption\":\"Asieris Pharmaceuticals Reports Strong 2024 Financial Results for Urogenital Cancer Drugs\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32124#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Asieris Pharmaceuticals Reports Strong 2024 Financial Results for Urogenital Cancer Drugs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Asieris Pharmaceuticals Reports Strong 2024 Financial Results for Urogenital Cancer Drugs - Insight, China&#039;s Pharmaceutical Industry","description":"hina-based urogenital cancer specialist Asieris Pharmaceuticals (SHA: 688176) has released its 2024 financial report. In its first year of commercialization, the company achieved revenues of RMB 202 million (USD 27.7 million) and maintained a cash reserve of RMB 1.89 billion (USD 260 million). Its flagship products, Ouyoubi (a neratinib biosimilar) and Dipaite (a pazopanib biosimilar), demonstrated impressive market uptake, covering 1,000 and 500 target hospitals respectively. Ouyoubi secured a 27% market share, while Dipaite achieved a 12% share of their respective originators.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=32124","og_locale":"en_US","og_type":"article","og_title":"Asieris Pharmaceuticals Reports Strong 2024 Financial Results for Urogenital Cancer Drugs","og_description":"hina-based urogenital cancer specialist Asieris Pharmaceuticals (SHA: 688176) has released its 2024 financial report. In its first year of commercialization, the company achieved revenues of RMB 202 million (USD 27.7 million) and maintained a cash reserve of RMB 1.89 billion (USD 260 million). Its flagship products, Ouyoubi (a neratinib biosimilar) and Dipaite (a pazopanib biosimilar), demonstrated impressive market uptake, covering 1,000 and 500 target hospitals respectively. Ouyoubi secured a 27% market share, while Dipaite achieved a 12% share of their respective originators.","og_url":"https:\/\/flcube.com\/?p=32124","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-21T07:02:58+00:00","article_modified_time":"2025-04-21T07:02:59+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2109.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=32124#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=32124"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Asieris Pharmaceuticals Reports Strong 2024 Financial Results for Urogenital Cancer Drugs","datePublished":"2025-04-21T07:02:58+00:00","dateModified":"2025-04-21T07:02:59+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=32124"},"wordCount":152,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=32124#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2109.webp","keywords":["Asieris Pharmaceuticals","Finanical Reports","SHA: 688176"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=32124#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=32124","url":"https:\/\/flcube.com\/?p=32124","name":"Asieris Pharmaceuticals Reports Strong 2024 Financial Results for Urogenital Cancer Drugs - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=32124#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=32124#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2109.webp","datePublished":"2025-04-21T07:02:58+00:00","dateModified":"2025-04-21T07:02:59+00:00","description":"hina-based urogenital cancer specialist Asieris Pharmaceuticals (SHA: 688176) has released its 2024 financial report. In its first year of commercialization, the company achieved revenues of RMB 202 million (USD 27.7 million) and maintained a cash reserve of RMB 1.89 billion (USD 260 million). Its flagship products, Ouyoubi (a neratinib biosimilar) and Dipaite (a pazopanib biosimilar), demonstrated impressive market uptake, covering 1,000 and 500 target hospitals respectively. Ouyoubi secured a 27% market share, while Dipaite achieved a 12% share of their respective originators.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=32124#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=32124"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=32124#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2109.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2109.webp","width":1080,"height":608,"caption":"Asieris Pharmaceuticals Reports Strong 2024 Financial Results for Urogenital Cancer Drugs"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=32124#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Asieris Pharmaceuticals Reports Strong 2024 Financial Results for Urogenital Cancer Drugs"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2109.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32124","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=32124"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32124\/revisions"}],"predecessor-version":[{"id":32127,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32124\/revisions\/32127"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/32126"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=32124"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=32124"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=32124"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}